RLAY

Over the past six months, Relay Therapeutics' stock has increased by 106.64%. The share price increased by 337.97% from May 7, 2025, to May 6, 2026. In Q1 2026, the company reported a quarterly loss of $0.41 per share, missing estimates, with revenues of $3 million, also falling short of estimates. In February 2026, Relay Therapeutics outlined anticipated 2026 clinical milestones for its zovegalisib program, which recently received Breakthrough Therapy designation from the FDA. In April 2026, Relay Therapeutics' stock cleared a key benchmark, achieving a 90-plus RS Rating and demonstrating market leadership with a jump to a 94 RS Rating.